Inventor

Edmund A. Rossi

Inventor

Woodland Park, NJ, US

Overview

2009–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 77 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides24%

A61KPreparations for medical, dental or toiletry purposes23%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%

B82YSpecific uses or applications of nanostructures12%

C12NMicroorganisms or enzymes11%

C12YEnzymes5%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%

Y02ATechnologies for adaptation to climate change2%

G01NInvestigating or analysing materials by determining their chemical or physical properties2%

H01QAntennas, i.e. radio aerials0%

PatentTitleYear

10,662,252Disease therapy by inducing immune response to Trop-2 expressing cells2020 10,308,688T-cell redirecting bispecific antibodies for treatment of disease2019 10,245,321Combination therapy for inducing immune response to disease2019 10,239,938T-cell redirecting bispecific antibodies for treatment of disease2019 10,183,992T-cell redirecting bispecific antibodies for treatment of disease2019 10,131,712Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors2018 10,111,954Combination therapy for inducing immune response to disease2018 9,963,507Therapeutic use of anti-CD22 antibodies for inducing trogocytosis2018 9,963,516Stable compositions of high-concentration allotype-selected antibodies for small-volume administration2018 9,931,413Tetrameric cytokines with improved biological activity2018 9,879,088'Disease therapy by inducing immune response to Trop-2 expressing cells'2018 9,872,920PEGylation by the dock and lock (DNL) technique2018 9,745,374'Fusion proteins containing recombinant cytotoxic RNAses'2017 9,737,617'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2017 9,682,143'Combination therapy for inducing immune response to disease'2017 9,683,050'Stable compositions of high-concentration allotype-selected antibodies for small-volume administration'2017 9,670,286'Disease therapy by inducing immune response to Trop-2 expressing cells'2017 9,663,576'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2017 9,617,531'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock'2017 9,540,618'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2017 9,540,435'Stably tethered structures of defined compositions with multiple functions or binding specificities'2017 9,498,542'Tetrameric cytokines with improved biological activity'2016 9,481,878'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2016 9,475,883'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2016 9,468,689'Ultrafiltration concentration of allotype selected antibodies for small-volume administration'2016 9,457,100'PEGylation by the dock and lock (DNL) technique'2016 9,446,123'Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy'2016 9,382,329'Disease therapy by inducing immune response to Trop-2 expressing cells'2016 9,359,443'Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases'2016 9,315,567'T-cell redirecting bispecific antibodies for treatment of disease'2016 9,192,664'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2015 9,184,781'Humanized antibodies and methods of humanizing antibodies'2015 9,180,205'Stable compositions of high-concentration allotype-selected antibodies for small-volume administration'2015 9,169,470'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2015 8,932,593'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2015 8,906,377'Stably tethered structures of defined compositions with multiple functions or binding specificities'2014 8,906,378'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases'2014 8,889,410'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,871,216'Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2014 8,865,176'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2014 8,829,175'Nucleic acids encoding polyvalent protein complexes'2014 8,771,987'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,697,080'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2014 8,658,773'Ultrafiltration concentration of allotype selected antibodies for small-volume administration'2014 8,597,659'Tetrameric cytokines with improved biological activity'2013 8,569,054'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,551,480'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2013 8,475,794'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases'2013 8,435,540'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO'2013 8,372,603'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,349,332'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2013 8,333,971'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2012 8,282,934'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2012 8,277,817'PEGylation by the dock and lock (DNL) technique'2012 8,246,960'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2012 8,211,440'Multivalent immunoglobulin-based bioactive assemblies'2012 8,192,739'Fusion proteins containing recombinant cytotoxic RNAses'2012 8,163,291'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2012 8,158,129'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo'2012 8,153,433'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2012 8,076,140'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2011 8,034,352'Tetrameric cytokines with improved biological activity'2011 8,003,111'Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo'2011 7,981,398'PEGylation by the dock and lock (DNL) technique'2011 7,906,121'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2011 7,906,118'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2011 7,871,622'Stably tethered structures of defined compositions with multiple functions or binding specificities'2011 7,858,070'Multivalent immunoglobulin-based bioactive assemblies'2010 7,785,880'Mammalian cell lines for increasing longevity and protein yield from cell culture'2010 7,666,400'PEGylation by the dock and lock (DNL) technique'2010 7,550,143'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2009 7,544,487'Fusion proteins containing recombinant cytotoxic RNAses'2009 7,537,930'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2009 7,534,866'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2009 7,531,327'Methods and compositions for increasing longevity and protein yield from a cell culture'2009 7,527,787'Multivalent immunoglobulin-based bioactive assemblies'2009 7,521,056'Stably tethered structures of defined compositions with multiple functions or binding specificities'2009

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2009–2020Patents assigned to IBC PHARMACEUTICALS INC (53)· patent assignee history

2009–2018Patents assigned to IMMUNOMEDICS INC (27)· patent assignee history

2009–2017Based in Nutley, NJ, US· patent location history

2010–2020Based in Woodland Park, NJ, US· patent location history

2011–2017Patents assigned to GOLDENBERG DAVID M (24)· patent assignee history

2011–2017Patents assigned to ROSSI EDMUND A (24)· patent assignee history

2011–2017Patents assigned to CHANG CHIEN-HSING (19)· patent assignee history

2014Based in Morris Plains, NJ, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IBC PHARMACEUTICALS INC	53	2009–2020
IMMUNOMEDICS INC	27	2009–2018
GOLDENBERG DAVID M	24	2011–2017
ROSSI EDMUND Aself	24	2011–2017
CHANG CHIEN-HSING	19	2011–2017

Locations

Location	Patents	Span
Woodland Park, New Jersey, US	64	2010–2020
Nutley, New Jersey, US	12	2009–2017
Morris Plains, New Jersey, US	1	2014